论文部分内容阅读
目的制备奇异变形杆菌-金黄葡萄球菌-铜绿假单胞菌(Proteus mirabilis-Staphylococcus aureus-Pseudomonas aeruginosa,PSP)吸附联合疫苗,并检测其对小鼠的保护效果。方法通过不同生产工艺制备奇异变形杆菌胞膜抗原(Proteus mirabilis membrane antigen,PMA)、金黄葡萄球菌胞质抗原(Staphylococcus aureus cytoplasmic antigen,SCA)金黄葡萄球菌类毒素抗原(Staphylococcus aureus toxoid antigen,SEA)及铜绿假单胞菌类毒素抗原(Pseudomonas aeruginosa toxoid antigen,PEA),按照一定配伍方式与Al(OH)_3佐剂形成PSP吸附联合疫苗,经腹腔注射小鼠,测定其保护效果。结果 6价PMA抗原对奇异变形杆菌6株疫苗株保护率为50%~100%;PSP吸附联合疫苗对奇异变形杆菌PM104的保护率为80%,对铜绿假单胞菌PA101的保护率为100%,对2株金黄葡萄球菌SA79和CMCC26002的保护率分别为90%和60%,对金黄葡萄球菌CMCC26002 α-毒素的保护率为70%。PSP吸附联合疫苗对同群异源菌株交叉保护率达70%以上的比例为:奇异变形杆菌占61.11%;金黄色葡萄球菌占50%;铜绿假单胞菌保护率占92.86%。结论 PSP吸附联合疫苗对疫苗株具有保护性,也对同群菌株具有保护性,为进一步临床研究提供了理论基础和技术支持。
Objective To prepare a combination vaccine of Proteus mirabilis-Staphylococcus aureus-Pseudomonas aeruginosa (PSP) and test its protective effect on mice. Methods Proteus mirabilis membrane antigen (PMA), Staphylococcus aureus cytoplasmic antigen (SCA) Staphylococcus aureus toxoid antigen (SEA) were prepared by different methods. Pseudomonas aeruginosa toxoid antigen (PEA), according to a certain compatibility with Al (OH) _3 adjuvant to form PSP adsorption combined vaccine, the mice were injected intraperitoneally to determine the protective effect. Results The protection rate of 6 strains of PMA antigen against 6 strains of Proteus mirabilis was 50% -100%. The protective rate of PSP combined vaccine against Pseudomonas sp. PM104 was 80% and that of Pseudomonas aeruginosa PA101 was 100% %, The protective rates of two strains of Staphylococcus aureus SA79 and CMCC26002 were 90% and 60%, respectively, and that of Staphylococcus aureus CMCC26002 a-toxin was 70%. The rate of the cross-protection rate of the PSP-adsorbed combined vaccine to heterologous strains of the same group was more than 70%: Proteus mirabilis accounted for 61.11%; Staphylococcus aureus accounted for 50%; Pseudomonas aeruginosa protection rate accounted for 92.86%. CONCLUSION: The PSP-conjugate combination vaccine is protective against vaccine strains and also protects the same-group strains, providing a theoretical basis and technical support for further clinical studies.